Skip to content

Source filing unavailable

Q3 2015 · —
Revenue$340.87M+11.2% vs Q3 2014+2.1% vs Q2 2015
Net Income$87.96M+241.4% vs Q3 2014−0.2% vs Q2 2015
EPS Diluted$1.39+239.0% vs Q3 2014−0.7% vs Q2 2015
Gross Profit$310,369,000+11.9%
Operating Income$131,532,000+126.6%
Operating Cash Flowderived$175,076,000+35.0%
Free Cash Flowderived$169,917,000+39.8%
Margins · derived
Gross margin91.1%+0.6 pt vs Q3 2014
Operating margin38.6%+19.7 pt vs Q3 2014
Net margin25.8%+17.4 pt vs Q3 2014

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2015Q3 2014Q3 2013Q3 2012
Revenue$340.87M$306.58M$232.16M$175.52M
Net Income$87.96M$25.77M$75.41M$33.21M
EPS Diluted$1.39$0.41$1.23$0.55

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR